Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute of Allergy and Infectious Diseases (NIAID) HIV Vaccine Trials Network |
---|---|
Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00413725 |
The purpose of this study is to determine the safety, efficacy, and tolerability of a three-dose regimen of an adenovirus-based HIV-1 vaccine in healthy South African adults.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Biological: MRKAd5 HIV-1 gag/pol/nef Other: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter Double-Blind Randomized Placebo-Controlled Phase IIB Test-of-Concept Study to Evaluate the Safety and Efficacy of a Three-Dose Regimen of the Clade B-Based Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine in HIV-1 Uninfected Adults in South Africa |
Enrollment: | 801 |
Study Start Date: | January 2007 |
Estimated Study Completion Date: | October 2011 |
Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Three doses of MRKAd5 HIV-1 gag/pol/nef vaccine
|
Biological: MRKAd5 HIV-1 gag/pol/nef
Experimental Clade-B based Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine
|
2: Placebo Comparator
Placebo
|
Other: Placebo
Placebo
|
The HIV epidemic is a major global health challenge. The Joint United Nations Program on HIV/AIDS (UNAIDS) reported that in 2004, 3 million people worldwide died of AIDS and an estimated 5 million people acquired HIV. Studies in animal models and observational data from humans suggest that cell-mediated immune responses may be key to controlling HIV infection. MRKAd5 HIV-1 gag/pol/nef, a clade B-based adenovirus serotype 5 HIV-1 vaccine, has been shown to elicit T-cell mediated immune responses. The vaccine appears to be safe and generally well tolerated in previous Phase 1 and 2 studies in HIV-uninfected people. The purpose of this study is to evaluate the safety and efficacy of the MRKAd5 HIV-1 gag/pol/nef vaccine in HIV-uninfected participants from South Africa, where clade C is predominant. The study will address whether a clade B-based vaccine designed to elicit T-cellular immunity will demonstrate efficacy in reducing acquisition of infection, or reducing HIV viral load in persons who become infected in a non-clade B region.
This study will last about 42 months for HIV-uninfected participants and 18 months for those who become HIV infected. Participants will be randomly assigned to receive 3 doses of either vaccine or placebo. All participants will receive their injections at study entry and at Months 1 and 6. Participants will be asked to complete a post-vaccination symptom log for the 3 days following each vaccination to monitor body temperature and symptoms known to be associated with the vaccine. At all study visits, participants will be asked about any adverse events they may have experienced. There will be at least 14 study visits over the first 4 years of the study. A physical exam, medication history, risk reduction counseling, and blood collection will occur at every visit. Participants will be asked to complete a social impact questionnaire at Weeks 12, 78, and 208; an outside testing and belief questionnaire at Weeks 30, 78, 130, 182, and 208; and a circumcision status assessment at Week 208. Participants will undergo HIV testing to check their HIV status approximately every 3 months.
Participants who become HIV infected during the study will have eight study visits at Weeks 4, 8, 12, 16, 20, 26, 52, and 78 post-diagnosis. A physical exam, risk reduction counseling, blood and urine collection, and a pregnancy test will occur at all visits. Genital secretion collection may also occur at some visits. Participants who become HIV infected and need to begin anti-HIV therapy will be discontinued from this study, but encouraged to enroll in the study HVTN 802.
As of September 17, 2007 enrollment and vaccinations for this study were suspended. Participants already enrolled have been asked to continue attending follow-up visits with this study.
Ages Eligible for Study: | 18 Years to 35 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
As of 9/19/07, clinical research sites were notified that HVTN 503 has been suspended; therefore, enrollment is discontinued and all participants will be unblinded and encouraged to continue follow-up visits.
Inclusion Criteria:
Exclusion Criteria:
South Africa | |
Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital | |
Johannesburg, South Africa | |
Aurum Institute for Health, KOSH District | |
Klerksdorp, South Africa | |
Cape Town HVTU | |
Mowbray, South Africa | |
Centre for the AIDS Program of Research in South Africa (CAPRISA) | |
Congella, South Africa | |
Medunsa HIV Research Unit | |
Medunsa, South Africa, 0204 SF |
Study Chair: | Glenda Gray, MD | Chris Hani Baragwanath Hospital |
Study Chair: | James Kublin, MD, MPH | Fred Hutchinson Cancer Research Center |
Responsible Party: | DAIDS ( Rona Siskind ) |
Study ID Numbers: | HVTN 503 |
Study First Received: | December 18, 2006 |
Last Updated: | May 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00413725 |
Health Authority: | United States: Food and Drug Administration; South Africa: Medicines Control Council |
HIV Seronegativity HIV Preventive Vaccine Adenovirus |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Adenoviridae Infections |
Sexually Transmitted Diseases Acquired Immunodeficiency Syndrome Retroviridae Infections Immunologic Deficiency Syndromes |
RNA Virus Infections Slow Virus Diseases Immune System Diseases Lentivirus Infections Infection |